[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100400557":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":40,"collaborators":7,"id":42,"slug":7,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":7,"maxAge":7,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Advanced Integrative Medical Science Institute","OTHER",null,[9],{"facility":10,"status":11,"city":12,"state":13,"zip":14,"country":15,"cosmosGeoPoint":16,"geoPoint":21,"contacts":22},"AIMS Institute","RECRUITING","Seattle","Washington","98102","United States",{"type":17,"coordinates":18},"Point",[19,20],-122.33207,47.60621,{"lat":20,"lon":19},[23,28,31,34,37,38],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"Michelle Speaks, MBA","CONTACT","2064201321","mspeaks@aimsinstitute.net",{"name":29,"role":25,"phone":26,"phoneExt":7,"email":30},"Sunil K Aggarwal, MD, PhD, FAAPMR","saggarwal@aimsinstitute.net",{"name":32,"role":33,"phone":7,"phoneExt":7,"email":7},"Therry Eparwa, DNP, ARNP, FNP-BC","PRINCIPAL_INVESTIGATOR",{"name":35,"role":36,"phone":7,"phoneExt":7,"email":7},"Leanna J Standish, ND, PhD, Lac, FABNO","SUB_INVESTIGATOR",{"name":29,"role":36,"phone":7,"phoneExt":7,"email":7},{"name":39,"role":36,"phone":7,"phoneExt":7,"email":7},"Sonia S Malani, ND",{"type":41,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100400557",false,"NCT04495790","AIMS Cancer Outcomes Study","Advanced Integrative Oncology Treatment for Adult and Pediatric Patients With Cancer: A Prospective Outcomes Study","ACOS","Inclusion Criteria:\n\n1. A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or\n2. An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute;\n3. If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment;\n4. If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient;\n5. A confirmed diagnosis of cancer based on medical oncology medical records.\n\nExclusion Criteria:\n\n1. Patients not diagnosed with cancer;\n2. Telehealth patients;\n3. Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires;\n4. Unwilling to participate in the AIMS Institute observational study.","ALL",{"count":51,"type":52},500,"ESTIMATED","5 Years","OBSERVATIONAL","The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.",[57,58,59,60,61],"Neoplasms","Neoplasm Malignant","Advanced Cancer","Advanced Solid Tumor","Oncology",[63,64,65,66,67],"Integrative Oncology","Naturopathic Oncology","Phytomedicine","Metabolic Therapy","Immunotherapy","2023-01-30",{"date":70,"type":71},"2023-02-01","ACTUAL",{"date":73,"type":71},"2020-05-18",{"date":75,"type":52},"2030-12-31",{"name":5,"class":6},1]